Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.

Critical reviews in oncogenesis - 1 Jan 2015

Garon Edward B, Abarca Phillip A, Strunck Jennifer L, Nameth Danielle, Neumann Catherine, Wolf Brian, Kim Kevin Y, Marx Caitlin, Elashoff Robert M

Abstract excerpt

Lung cancer is the leading cause of cancer mortality. Great advances in non-small cell lung cancer therapy have been seen in the last decade, beginning with the success in treating lung cancer harboring EGFR mutations and ALK-gene rearrangements. The potential of these biomarker-driven therapies has propelled research in biomarker targeted approaches to the forefront of lung cancer research. The successful...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to ErbB Receptors

Share to ALK gene

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 27279233
DOI: 10.1615/CritRevOncog.v20.i5-6.70
PMCID: PMC5273860

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.PMID 27279233Read ↗

The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.Semantic proximity Read ↗

Impact of Molecular Biomarker Test Availability and Timing on Metastatic Non-Small-Cell Lung Cancer Treatment Selection and Clinical Outcomes in the U.S. Medicare PopulationSemantic proximity Read ↗

The rapidly evolving landscape of biomarker testing in non-small cell lung cancer.Semantic proximity Read ↗

Innovative Clinical Trials: The LUNG-MAP Study.Semantic proximity Read ↗

Pharmacodynamic biomarkers: falling short of the mark?Semantic proximity Read ↗

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.Semantic proximity Read ↗

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.Semantic proximity Read ↗

What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?Semantic proximity Read ↗

Biomarker testing in non-small cell lung cancer: a clinician's perspective.Semantic proximity Read ↗

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.